Staphylococcus Aureus Bloodstream Infection / AZD7760 · Phase 1 Trial

A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults

ClinicalTrials.gov · August 18, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a Phase 1 trial registration for AZD7760, a novel agent, conducted in healthy Japanese adults to characterise safety and pharmacokinetics. No efficacy data, clinical outcomes, or results are reported in this registry record; only study design and planned endpoints are available.

What was studied

Phase 1, Interventional, Randomized, Parallel, Double masking, Prevention purpose. Staphylococcus Aureus Bloodstream Infection; age from 18 Years; to 55 Years; accepts healthy volunteers. Intervention: Cohort 1 (AZD7760 Dose A); Cohort 2 (AZD7760 Dose B). Compared with: Pooled Placebo — Placebo Comparator. n = 18. 1 site: Japan.

Key findings

Safety

Recruitment is ongoing (status: RECRUITING); no safety or pharmacokinetic data are available.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a Phase 1 safety and pharmacokinetics study in healthy volunteers with no results yet posted; it describes planned work only.

Study design

As stated by the source record.

MethodsPrimary outcome measures: Occurrence of Adverse Events (AEs) (assessed at Day 1 to Day 181); Occurrence of Medically-attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (assessed at Day 1 to Day 361)

DesignPhase 1, Interventional, Randomized, Parallel, Double masking, Prevention purpose

PopulationStaphylococcus Aureus Bloodstream Infection; age from 18 Years; to 55 Years; accepts healthy volunteers

Sample size18

InterventionCohort 1 (AZD7760 Dose A); Cohort 2 (AZD7760 Dose B)

ComparatorPooled Placebo — Placebo Comparator

Setting1 site: Japan

Reported figures

Quoted from the source exactly as published.

Planned enrollment18

Study phasePhase 1

Primary outcome measure 1Occurrence of Adverse Events (AEs), Day 1 to Day 181

Primary outcome measure 2Occurrence of Medically-attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs), Day 1 to Day 361

Caveats

This is a registry record only; no trial results are reported.
Recruitment is ongoing (status: RECRUITING); no safety or pharmacokinetic data are available.
Study is in healthy volunteers, not patients with S. aureus infection, limiting direct clinical relevance.
Randomization method, blinding specification, dose, duration of infusion, and follow-up visit schedule not detailed in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 1, placebo-controlled, but design details beyond phase not fully specified.

Directness

limited

Healthy volunteers; condition listed is S. aureus bacteremia but population enrolled are healthy adults.

Consistency

insufficient

No results reported; consistency cannot be assessed at registry stage.

Risk of bias

insufficient

Placebo mentioned but blinding, allocation concealment, and other bias mitigation not described.

Sample adequacy

limited

Estimated enrollment 18 participants total; typical Phase 1 size but modest for firm conclusions.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07612813). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 18 participants (ESTIMATED). Conditions: Staphylococcus Aureus Bloodstream Infection. Interventions: DRUG: AZD7760; OTHER: Placebo. Primary outcome measures: Occurrence of Adverse Events (AEs) , Day 1 to Day 181; Occurrence of Medically-attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) , Day 1 to Day 361. Brief summary: The purpose of this study is to evaluate the safety and PK of AZD7760 when given as an intravenous (IV) infusion to healthy Japanese adult participants.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Staphylococcus Aureus Bloodstream InfectionNCT07612813AZD7760AstraZeneca